Source: Newsfile

Press Release: Soligenix : Catalyst Watch: Soligenix Inc.'s SGX301 and SGX942 Upcoming Data Release Can Change the CTCL and Oral Mucositis Treatment Landscape

Miami Beach, Florida--(Newsfile Corp. - October 22, 2019) - There are two things that developing biotechs need for success. First, they need a good drug. Second, they need cash to fund clinical trials. Soligenix has both (NASDAQ: SNGX). Combined, the two may offer Soligenix investors a near-term opportunity to enjoy the rewards of both an FDA approval and the subsequent commercial launch of at least two promising drugs, SGX301 and SGX942, each targeting unmet ...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Christopher J. Schaber's photo - Chairman & CEO of Soligenix

Chairman & CEO

Christopher J. Schaber

CEO Approval Rating

88/100

Soligenix is a late-stage biopharmaceutical company that researches and develops novel vaccines for the treatment of cancer and infectious diseases. Read more